Thermo Fisher Scientific (TMO) Stake Decreased by Bristol John W & Co. Inc. NY

Bristol John W & Co. Inc. NY decreased its position in shares of Thermo Fisher Scientific (NYSE:TMO) by 1.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 356,194 shares of the medical research company’s stock after selling 4,795 shares during the period. Thermo Fisher Scientific comprises 2.1% of Bristol John W & Co. Inc. NY’s portfolio, making the stock its 23rd biggest position. Bristol John W & Co. Inc. NY’s holdings in Thermo Fisher Scientific were worth $73,540,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Icon Wealth Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $105,000. Keeler Thomas Management LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $106,000. Virtue Capital Management LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $127,000. Johnson Financial Group Inc. grew its stake in shares of Thermo Fisher Scientific by 2,608.7% during the first quarter. Johnson Financial Group Inc. now owns 623 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 600 shares during the last quarter. Finally, Premia Global Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $131,000. 85.86% of the stock is owned by institutional investors.

Several analysts have recently commented on TMO shares. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Thursday, April 5th. Bank of America increased their price target on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Thursday, April 26th. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Barclays increased their price target on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $224.38.

In other news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 5th. The shares were sold at an average price of $204.60, for a total transaction of $511,500.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 40,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the transaction, the chief executive officer now directly owns 334,622 shares in the company, valued at $70,324,159.52. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,706 shares of company stock worth $8,962,073. Insiders own 0.49% of the company’s stock.

Shares of Thermo Fisher Scientific opened at $208.27 on Friday, MarketBeat Ratings reports. Thermo Fisher Scientific has a 52-week low of $170.07 and a 52-week high of $226.44. The company has a market capitalization of $84.07 billion, a price-to-earnings ratio of 21.95, a price-to-earnings-growth ratio of 1.53 and a beta of 1.14. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The firm had revenue of $5.85 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same period last year, the firm earned $2.08 earnings per share. The business’s revenue for the quarter was up 22.8% on a year-over-year basis. equities analysts anticipate that Thermo Fisher Scientific will post 10.9 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, July 16th. Stockholders of record on Friday, June 15th will be given a dividend of $0.17 per share. The ex-dividend date is Thursday, June 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is 7.17%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply